S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN

Ngā tūemi rite

• S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
  mā: Frank G Rücker, me ētahi atu.
  I whakaputaina: (2023-08-01)
• Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
  mā: Frank G. Rücker, me ētahi atu.
  I whakaputaina: (2024-07-01)
• Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML
  mā: Sibylle Cocciardi, me ētahi atu.
  I whakaputaina: (2025-01-01)
• Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
  mā: Katrin Teich, me ētahi atu.
  I whakaputaina: (2021-05-01)
• Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype
  mā: Frank G. Rücker, me ētahi atu.
  I whakaputaina: (2018-01-01)